Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

About this episode

David Rubin, MD discusses the gap between IBD therapies and patient outcomes, emphasizing treatment strategies and monitoring.

Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class. Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therapies-and-patient-outcomes-with-david-rubin-md

People in this episode

Guest: David Rubin, MD

Topics covered

• IBD therapies
• patient outcomes
• remission strategies
• treatment monitoring
• Crohn's disease
• ulcerative colitis

Keywords

• IBD
• therapies
• patient outcomes
• remission
• Crohn's disease
• ulcerative colitis
• treatment strategies

Mentioned in this episode

Organizations: University of Chicago Medicine, HCPLive.com

Products: Crohn's disease, ulcerative colitis

More episodes of HCPLive Podcasts

• Joint Ventures: EULAR 2026 Congress Preview · May 29, 2026 · 43 min
• Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus · May 28, 2026 · 36 min
• Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier · May 28, 2026 · 30 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2 · May 28, 2026 · 28 min
• Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1 · May 28, 2026 · 29 min
• Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms · May 28, 2026 · 25 min